Recent advances in prevention of sepsis in the premature neonates in NICU

Early Human Development

Volumn 87, Issue SUPPL., 2011, Pages

  Manzoni, P ^a   Rizzollo, S ^a   Decembrino, L ^d   Ruffinazzi, G ^d   Rossi Ricci, A ^d   Gallo, E ^a   Stolfi, I ^c   Mostert, M ^b   Stronati, M ^d   Farina, D ^a  

^a S ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Fluconazole; Infection; Lactoferrin; Neonate; Preterm; Prevention; Sepsis

Indexed keywords

FLUCONAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LACTOFERRIN; PAGIBAXIMAB; PALIVIZUMAB; PLACEBO; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYGIENE; MYCOSIS; NEWBORN INTENSIVE CARE; NONHUMAN; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEPSIS; STAPHYLOCOCCUS INFECTION; VERY LOW BIRTH WEIGHT;

ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; COST OF ILLNESS; DRUG DELIVERY SYSTEMS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; INTENSIVE CARE, NEONATAL; SEPSIS;

EID: 79951811072     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.01.008     Document Type: Article

References (19)

1. Kaufman D., Fairchild K.D. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev 2004, 17(3):638-680.
2. Stoll B.J., Hansen N.I., Adams-Chapman I., et al. National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low birth-weight infants with neonatal infection. JAMA. 2004, 292(19):2357-2365.
3. Schanler R.J., Lau C., Hurst N.M., Smith E.O. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. Pediatrics 2005, 116(2):400-406.
4. Schanler R.J., Shulman R.J., Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999, 103:1150-1157.
5. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics Aug, 2002, 110(2 Pt 1):285-291.
6. Bendel C.M., Wiesner S.M., Garni R.M., Cebelinski E., Wells C.L. Cecal colonization and systemic spread of Candida albicans in mice treated with antibiotics and dexamethasone. Pediatr Res Mar, 2002, 51(3):290-295.
7. Bianconi S., Gudavalli M., Sutija V.G., Lopez A.L., Barillas-Arias L., Ron N. Ranitidine and late-onset sepsis in the NICU. J Perinat Med 2007, 35(2):147-150.
8. Huang Y.C., Su L.H., Wu T.L., Lin T.Y. Genotyping analysis of colonizing candidal isolates from very-low-birth weight infants in a neonatal intensive care unit. J Hosp Infect Nov, 2004, 58(3):200-203.
9. Deshpande G., Rao S., Patole S., Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125:921-930.
10. Ronayne de Ferrer P.A., Baroni A., Sambucetti M.E., Lopez N.E., Cerian Cernadas J.M. Lactoferrin levels in term and preterm milk. J Am Coll Nutr 2000, 19(3):370-373.
11. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 2004, 17(3):189-196.
12. Paolo Manzoni, Matteo Rinaldi, Silvia Cattani, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates a randomized trial. JAMA 2009, 302(13):1421-1428.
13. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics Sep, 1998, 102(3 Pt 1):531-537.
14. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr Oct, 2003, 143(4):532-540.
15. From the American Academy of Pediatrics: policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics Dec, 2009, 124(6):1694-1701. AAP Committee on Infectious Diseases, Epub 2009 Sep 7.
16. Berger A., Obwegeser E., Aberle S.W., Langgartner M., Popow-Kraupp T. Nosocomial transmission of respiratory syncytial virus in neonatal intensive care and intermediate care units: a prospective epidemiologic study. Pediatr Infect Dis J Jul, 2010, 29(7):669-670.
17. Kaufman D.A., Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol Sep, 2010, 37(3):611-628.
18. Weisman L.E., Fischer G.W., Thackray H.M., Johnson K.E., Schuman R.F., Mandy G.T., et al. Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol May, 2009, 9(5):639-644. Epub 2009 Mar.
19. Weisman L.E., Thackray H.M., Garcia-Prats J.A., Nesin M., Schneider J.H., Fretz J., et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother Jul, 2009, 53(7):2879-2886.